[11C]Flumazenil brain uptake is influenced by the blood-brain barrier efflux transporter P-glycoprotein
Authors:
- Femke E FroklageFFFemke E Froklage
- Stina SyvänenSSStina Syvänen
- N Harry HendrikseNHN Harry Hendrikse
- Marc C HuismanMHMarc C Huisman
- Carla Fm MolthoffCMCarla Fm Molthoff
- Yoshihiko TagawaYTYoshihiko Tagawa
- Jaap C ReijneveldJRJaap C Reijneveld
- Jan J HeimansJHJan J Heimans
- Adriaan A LammertsmaALAdriaan A Lammertsma
- Jonas ErikssonJEJonas Eriksson
- Elizabeth Cm de LangeELElizabeth Cm de Lange
- Rob A VoskuylRVRob A Voskuyl
Open Access
- 28 March 2012
- journal article
- Published by Springer Nature in EJNMMI Research
- Vol. 2 (1) , 12
Abstract
Background: [11C]Flumazenil and positron emission tomography (PET) are used clinically to assess gamma-aminobutyric acid (GABA)-ergic function and to localize epileptic foci prior to resective surgery. Enhanced P-glycoprotein (P-gp) activity has been reported in epilepsy and this may confound interpretation of clinical scans if [11C]flumazenil is a P-gp substrate. The purpose of this study was to investigate whether [11C]flumazenil is a P-gp substrate. Methods: [11C]Flumazenil PET scans were performed in wild type (WT) (n = 9) and Mdr1a/1b, (the genes that encode for P-gp) double knockout (dKO) (n = 10) mice, and in naive rats (n = 10). In parallel to PET scanning, [11C]flumazenil plasma concentrations were measured in rats. For 6 of the WT and 6 of the dKO mice a second, [11C]flumazenil scan was acquired after administration of the P-gp inhibitor tariquidar. Cerebral [11C]flumazenil concentrations in WT and Mdr1a/1b dKO mice were compared (genetic disruption model). Furthermore, pre and post P-gp-blocking cerebral [11C]flumazenil concentrations were compared in all animals (pharmacological inhibition model). Results: Mdr1a/1b dKO mice had approximately 70% higher [11C]flumazenil uptake in the brain than WT mice. After administration of tariquidar, cerebral [11C]flumazenil uptake in WT mice increased by about 80% in WT mice, while it remained the same in Mdr1a/1b dKO mice. In rats, cerebral [11C]flumazenil uptake increased by about 60% after tariquidar administration. Tariquidar had only a small effect on plasma clearance of flumazenil. Conclusions: The present study showed that [11C]flumazenil is a P-gp substrate in rodents. Consequently, altered cerebral [11C]flumazenil uptake, as observed in epilepsy, may not reflect solely GABAA receptor density changes but also changes in P-gp activity.Keywords
This publication has 24 references indexed in Scilit:
- Transport of Selected PET Radiotracers by Human P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2): An In Vitro ScreeningJournal of Nuclear Medicine, 2011
- (R)-[11C]Verapamil PET studies to assess changes in P-glycoprotein expression and functionality in rat blood-brain barrier after exposure to kainate-induced status epilepticusBMC Medical Imaging, 2011
- The “Specific” P-Glycoprotein Inhibitor Tariquidar Is Also a Substrate and an Inhibitor for Breast Cancer Resistance Protein (BCRP/ABCG2)ACS Chemical Neuroscience, 2010
- Tariquidar inhibition of P-glycoprotein activity in patients with temporal lobe epilepsy measured with PET and (R)-[C-11]VerapamilNeuroImage, 2010
- Changes in GABAA receptor properties in amygdala kindled animals: In vivo studies using [11C]flumazenil and positron emission tomographyEpilepsia, 2009
- Accuracy of 3-Dimensional Reconstruction Algorithms for the High-Resolution Research TomographJournal of Nuclear Medicine, 2008
- Tariquidar-Induced P-Glycoprotein Inhibition at the Rat Blood–Brain Barrier Studied with (R)-11C-Verapamil and PETJournal of Nuclear Medicine, 2008
- [11C]Flumazenil PET in Temporal Lobe Epilepsy: Do We Need an Arterial Input Function or Kinetic Modeling?Journal of Cerebral Blood Flow & Metabolism, 2007
- Performance evaluation of the ECAT HRRT: an LSO-LYSO double layer high resolution, high sensitivity scannerPhysics in Medicine & Biology, 2007
- Synthesis of ethyl 8-fluoro-5,6-dihydro5- [11C]methyl-6-oxo-4H-imidazo[1,5-a] [1,4]benzodiazepine-3-carboxylate (RO 15.1788-11C): A specific radioligand for the in vivo study of central benzodiazepine receptors by positron emission tomographyThe International Journal of Applied Radiation and Isotopes, 1984